UpdatesPress Release

Caplin Point's subsidiary, Caplin Steriles, secured approval for Desmopressin Acetate Injection.

Caplin Point Laboratories Limited logo
Caplin Point Laboratories LimitedCAPLIPOINT · Filed with the exchange

This generic drug targets a US market with annual sales of approx. 215.8 Cr ($26 million), enhancing future revenue potential.

Read the original filing(PDF)

No comments yet. Be the first.

More from Caplin Point Laboratories Limited

All announcements